Laboratórna Diagnostika
Published December 6, 2021 | Version v1
Journal article Open

Porovnanie point-of-care analyzátora s konvenčnými laboratórnymi metódami pre stanovenie lipidov / Comparison of a point-of-care analyzer with clinical diagnostic laboratory methods for the determination of lipids

Creators

  • 1. Ústav výživy a genomiky, Fakulta agrobiológie a potravinových zdrojov, Slovenská poľnohospodárska univerzita v Nitre

Description

SÚHRN

Testovacie zariadenia point-of-care (POC) sa používajú na skríning dyslipidémie a na monitorovanie hladín lipidov u pacientov. Cieľom pilotnej štúdie bolo vyšetriť základné lipidové parametre POC analyzátorom Cholestech LDX a porovnať so štandardnými diagnostickými laboratórnymi metódami (CDLM). U 118 jedincov boli zmerané hladiny celkového cholesterolu (TC), triacylglycerolov (TG), HDL cholesterolu (HDL-C) a LDL cholesterolu (LDL-C). Zmerané koncentrácie sledovaných lipidov kazetovými testami POC zaradené do nízkeho, stredného a vysokého rozsahu boli v súlade s hodnotami získanými pomocou CLDM, s výnimkou stredného rozsahu, kde hladiny TC a LDL-C boli podhodnotené (p < 0,01). Všetky parametre základného lipidového panelu merané analyzátorom POC významne korelovali s CDLM (p < 0,001). Analyzátor Cholestech LDX pre POC testovanie je nástroj s primeraným analytickým výkonom a veľmi dobrou koreláciou. Poskytol spoľahlivú alternatívu ku konvenčným laboratórnym metódam pre skríning rizikových faktorov chronických chorôb u náhodne vybraných jedincov bez klinickej manifestácie symptómov kardiovaskulárnych chorôb.

ABSTRACT

Point-of-care (POC) testing devices can be used to screen for dyslipidemia and to monitor lipid levels of patients. The aim of our study was assessment of basic lipid parameters used the Cholestech LDX analyzer and compared to clinical diagnostic laboratory methods (CDLM). In 118 individuals total cholesterol (TC), triglycerides (TG), HDL cholesterol (HDL-C) and LDL cholesterol (LDL-C) levels were measured. Data were evaluated for conformance with National Cholesterol Education Program (NCEP) guidelines. Results were grouped into low, middle and high ranges and were similar to those obtained by CLDM, except in the middle range where TC and LDL-C levels were underestimated by Cholestech LDX (p < 0.01). All analytes measured by POC analyzer correlated significantly with CDLM (p < 0.001). The Cholestech LDX analyzer for POC testing is a tool with adequate analytical performance and very good correlation. It provided a reliable alternative to conventional laboratory methods for screening for chronic disease risk factors in randomly selected individuals without clinically manifest symptoms of cardiovascular diseases.

Notes

Táto práca bola podporená vedeckými grantmi VEGA 1/0144/19 MŠ SR a ITMS: 313011V344 spolufinancovaný zo zdrojov Európskeho fondu regionálneho rozvoja. This work was supported by scientific grants VEGA 1/0144/19 MŠ SR and ITMS: 313011V344 co-financed from the European Regional Development Fund.

Files

Laboratórna Diagnostika XXVI_2_2021 74-82.pdf

Files (491.1 kB)

Name Size Download all
md5:4c3ec6c69092fdec9cb239fcfaa5dde0
491.1 kB Preview Download

Additional details

References

  • Alberty, R., Studenčan, M., Kovář, F. (2017): Prevalence of conventional cardiovascular risk factors in patients with acute coronary syndromes in Slovakia. Central European Journal of Public Health, 25(1), pp. 77–84. doi:10.21101/cejph.a4351.
  • Barter, P. J., Rye, K. A. (1996): High density lipoproteins and coronary heart disease. Atherosclerosis, 121(1), pp. 1–12. doi:10.1016/0021-9150(95)05675-0.
  • Carey, M. et al. (2006): Validation of a point of care lipid analyser using a hospital-based reference laboratory. Irish journal of medical science, 175(4), pp. 30–35.
  • Dale, R. A., Jensen, L. H., Krantz, M. J. (2008): Comparison of two point-of-care lipid analyzers for use in global cardiovascular risk assessments. Annals of Pharmacotherapy, 42(5), pp. 633–639. doi:10.1345/aph.1K688.
  • Expert panel on detection, evaluation, and treatment of high cholesterol in adults. (2001): Executive summary of the third report of the National Expert Panel on detection, evaluation, and treatment of high cholesterol in adults (Adult Treatment Panel III). JAMA, 285, pp. 2486–2497.
  • Friedewald, W. T., Levy, R. I., Frederickson, D. S. (1972): Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry, 18, pp. 499–502.
  • Glasziou, P. P. et al. (2008): Monitoring cholesterol levels: Measurement error or true change? Annals of Internal Medicine, 148(9), pp. 656–661. doi: 10.7326/0003-4819-148-9-200805060-00005
  • Cheng, S. Y. et al. (2020): Performance evaluation of a new mobile POC lipids analyzer. Journal of Medical and Biological Engineering, 40(1), pp. 143–148. doi:10.1007/s40846-019-00495-6.
  • Menown, I. B. A. et al. (2009): Dyslipidemia therapy update: the importance of full lipid profile assessment. Advances in Therapy, 26(7), pp. 711–718. doi:10.1007/s12325-009-0052-3.
  • NCEP (1995): National Cholesterol Education Program. Recommendations on lipoprotein measurement from the working group on lipoprotein measurement. U.S. National Institutes of Health; 1995.
  • O'Donovan, D. Ó. et al. (2011): Precision of a point of care testing device for lipid profiling. European Journal of Lipid Science and Technology, 113(10), pp. 1230–1234. doi:10.1002/ejlt.201100185.
  • Panz, V. R. et al. (2005): Performance of the CardioChekTM PA and Cholestech LDX® point-of-care analysers compared to clinical diagnostic laboratory methods for the measurement of lipids: cardiovascular topic. Cardiovascular Journal of South Africa, 16(2), pp. 112–116.
  • Shemesh, T. et al. (2006): Agreement between laboratory results and on-site pathology testing using Bayer DCA2000+ and Cholestech LDX point-of-care methods in remote Australian Aboriginal communities. Clinical Chimica Acta, 367, pp. 69–76. doi:10.1016/j.cca.2005.11.014.
  • Shephard, M., Tallis, G. (2002): Assessment of the point-of-care Cholestech lipid analyser for lipid screening in Aboriginal communities. Australian Journal of Medical Science, 23(1), pp. 4–10.
  • Whitehead, S. J., Ford, C., Gama, R. (2014a): The impact of different point-of-care testing lipid analysers on cardiovascular disease risk assessment. Journal of Clinical Pathology, 67(6), pp. 535–569. doi:10.1136/jclinpath-2013-202123.
  • Whitehead, S. J., Ford, C., Gama, R. (2014b): A combined laboratory and field evaluation of the Cholestech LDX and CardioChek PA point-of-care testing lipid and glucose analysers. Annals of clinical biochemistry, 51(1), pp. 54–67. doi:10.1177/0004563213482890.
  • WHO (2021): Cardiovascular diseases (CVDs). Dostupné na: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (cit: 11. jún 2021)
  • Zhang, P. D. et al. (2015): Blood lipid profiles and factors associated with dyslipidemia assessed by a point-of-care testing device in an outpatient setting: A large-scale cross-sectional study in Southern China. Clinical biochemistry, 48(9), pp. 586–589. doi:10.1016/j.clinbiochem.2015.03.008.